Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations

Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world. Progression toward non-alcoholic steatohepatitis (NASH) is associated with alterations of skeletal muscle. One plausible mechanism for altered muscle compartment in liver dis...

Full description

Bibliographic Details
Main Authors:	Camille Pichon, Maxime Nachit, Justine Gillard, Greetje Vande Velde, Nicolas Lanthier, Isabelle A. Leclercq
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Nutrition
Subjects:	MAFLD (metabolic-associated fatty liver disease) NASH (non-alcoholic steatohepatitis) ammonia myosteatosis L-ornithine L-aspartate
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2022.1051157/full

Similar Items

Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy
by: Claudia Isabel Blanco Vela, et al.
Published: (2011-01-01)

Efficacy of L-Ornithine L-Aspartate in Recovery of Patients Suffering from Acute Viral Hepatitis
by: Ebtihal Bilal, et al.
Published: (2023-06-01)

Effects of L-Ornithine-L-Aspartate on Angiogenesis and Perfusion in Subacute Hind Limb Ischemia: Preliminary Study
by: Sanghoon Jung, et al.
Published: (2024-08-01)

Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
by: Roger F. Butterworth, et al.
Published: (2019-03-01)

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
by: Kapil Sharma, et al.
Published: (2014-01-01)

Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis With Sarcopenic Obesity
by: Zi-Xuan Wang, et al.
Published: (2022-03-01)

EXPERIENCE OF ORNITHINE ASPARTATE (HEPA-MERZ) AND PROBIOTICS BIOFLORUM FORTE IN THE TREATMENT OF NON-SEVERE FORMS OF ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASE
by: L. Yu. Ilchenko, et al.
Published: (2016-10-01)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
by: Maxime Nachit, et al.
Published: (2021-02-01)

POSSIBILITIES TO USE L-ORNITINE-L-ASPARTATE IN THERAPY OF NON-ALCOHOL FATTY LIVER DISEASE PATIENTS
by: L. A. Teterina, et al.
Published: (2017-11-01)

Results of using L-ornitin-L-aspartate in the treatment of hepatic encephalopathy in liver transplantation
by: S. E. Voskanyan, et al.
Published: (2021-09-01)

Intravenous versus oral ‘l-ornithine-l-aspartate’ in overt hepatic encephalopathy: a randomized comparative study
by: Ashok Jhajharia, et al.
Published: (2024-05-01)

Asthenia and fatigue in hyperammonemia: etiopathogenesis and methods of correction
by: E. Yu. Plotnikova, et al.
Published: (2022-01-01)

L-Ornithine-L-Aspartate and Intermittent Renal Replacement Therapy in Fulminant Hepatitis A
by: Nourhane Obeid, et al.
Published: (2023-03-01)

Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats
by: Laura Bainy Rodrigues de Freitas, et al.
Published: (2022-11-01)

Comparison of the Ornithine Carbamyltransferase with Aspartate Aminotransferase and Alanine Aminotransferase in patients with liver diseases
by: HR.Joshaghani, et al.
Published: (2002-09-01)

Comparative chemoreactomic analysis of ornithine aspartate, S-ademethionine and ursodeoxycholic acid
by: I. Yu. Torshin, et al.
Published: (2022-01-01)

Oral Administration of L-Citrulline, but not L-Arginine or L-Ornithine, Acts as a Hypothermic Agent in Chicks
by: Vishwajit S. Chowdhury, et al.
Published: (2015-10-01)

Different types of hyperammonemia in clinical practice
by: E. Yu. Plotnikova, et al.
Published: (2018-10-01)

HYPERAMMONIUM IN PATIENTS WITH PRECIRRHOSIS STAGE: CLINICAL REALITY?
by: L. Yu. Ilchenko, et al.
Published: (2018-06-01)

Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate
by: Hendrik Strebel, et al.
Published: (2020-04-01)

Metabolic Engineering of Bacillus amyloliquefaciens to Efficiently Synthesize L-Ornithine From Inulin
by: Yifan Zhu, et al.
Published: (2022-06-01)

Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage
by: A O Buyeverov, et al.
Published: (2019-02-01)

Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study
by: Jorge Luis Poo, et al.
Published: (2006-10-01)

Systematic pathway engineering of Corynebacterium glutamicum S9114 for l-ornithine production
by: Bin Zhang, et al.
Published: (2017-09-01)

A Simple Algorithm for Semiquantitative Analysis of Scored Histology Data in the R Environment, on the Example of Murine Non-Alcoholic Steatohepatitis Pharmacotherapy
by: Veronika A. Prikhodko, et al.
Published: (2022-12-01)

Hepatic encephalopathy: features of pharmacotherapy
by: A. V. Polukhina, et al.
Published: (2018-04-01)

Optimization of ʟ-ornithine production in recombinant Corynebacterium glutamicum S9114 by cg3035 overexpression and manipulating the central metabolic pathway
by: Bin Zhang, et al.
Published: (2018-06-01)

Super-anti-freezing, tough and adhesive titanium carbide and L-ornithine-enhanced hydrogels
by: Zhangkang Li, et al.
Published: (2023-05-01)

Recent Advances of L-ornithine Biosynthesis in Metabolically Engineered Corynebacterium glutamicum
by: Xiao-Yu Wu, et al.
Published: (2020-01-01)

Thermal Deformations of Crystal Structures in the L-Aspartic Acid/L-Glutamic Acid System and DL-Aspartic Acid
by: Roman Sadovnichii, et al.
Published: (2021-09-01)

Supplementation of L-Ornithine Could Increase Sleep-like Behavior in the Mouse Pups
by: Mayumi Takakura, et al.
Published: (2022-12-01)

Oral Administration of D-aspartate, but not of L-aspartate, Reduces Food Intake in Chicks
by: Edi Erwan, et al.
Published: (2013-04-01)

Proteome analysis guided genetic engineering of Corynebacterium glutamicum S9114 for tween 40-triggered improvement in l-ornithine production
by: Yan Jiang, et al.
Published: (2020-01-01)

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
by: Nicolas Lanthier, et al.
Published: (2022-08-01)

L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinson’s Disease Models
by: Maria Josè Sisalli, et al.
Published: (2022-09-01)

Ornithine Transcarbamylase Deficiency in Iranian Children
by: HR Joshaghani, et al.
Published: (2003-06-01)

Ornithine Transcarbamylase Deficiency in Iranian Children
by: HR Joshaghani, et al.
Published: (2003-08-01)

L-Ornithine derivatives with structural hetaryl and alkyl moiety: Synthesis and antibacterial activity
by: T. G. Bodrova, et al.
Published: (2024-07-01)

Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement)
by: M. Yu. Nadinskaia, et al.
Published: (2024-03-01)

Improvement in l-ornithine production from mannitol via transcriptome-guided genetic engineering in Corynebacterium glutamicum
by: Libin Nie, et al.
Published: (2022-09-01)